Tumour-initiating cells, or cancer stem cells (CSCs), possess stem-cell-like properties observed in normal adult tissue stem cells. Normal and cancerous stem cells may therefore share regulatory mechanisms for maintaining self-renewing capacity and resisting differentiation elicited by cell-intrinsic or microenvironmental cues. Here, we show that miR-199a promotes stem cell properties in mammary stem cells and breast CSCs by directly repressing nuclear receptor corepressor LCOR, which primes interferon (IFN) responses. Elevated miR-199a expression in stem-cell-enriched populations protects normal and malignant stem-like cells from differentiation and senescence induced by IFNs that are produced by epithelial and immune cells in the mammary gland. Importantly, the miR-199a-LCOR-IFN axis is activated in poorly differentiated ER − breast tumours, functionally promotes tumour initiation and metastasis, and is associated with poor clinical outcome. Our study therefore reveals a common mechanism shared by normal and malignant stem cells to protect them from suppressive immune cytokine signalling.
The mammary gland epithelium is a hierarchically organized tissue with multipotent mammary stem cells (MaSCs) capable of generating luminal and basal epithelial cells 1 . It has been hypothesized that regulators of normal stem cell activity may be exploited by tumour-initiating cells (TICs) or cancer stem cells (CSCs) 2 . Indeed, recent studies have revealed several cell fate regulators as such molecular links between MaSCs and breast TICs that drive their renewal activity in both normal and cancerous mammary gland tissues [3] [4] [5] . Poorly differentiated tumours, typically basal-like/claudin-low or triple-negative breast tumours 6, 7 , have high TIC activity and are enriched in CD24 − /CD44 + breast CSCs 8 , which resemble some features of normal MaSCs 5, 9, 10 .
Besides their cell-intrinsic self-renewal ability, normal stem cells need to adopt additional mechanisms to fend off microenvironmental pressure that may deplete the stem cell pool. Although immune cells have been reported to be critical players in mammary gland development 11 , it is unknown how MaSCs control their interaction with the immune cells to sustain their stem cell activity. Interestingly, stem cells have been shown to downregulate immunogenic factors, such as major histocompatibility complexes (MHCs), to protect themselves from immune surveillance and ensure tissue regeneration 12 . This mechanism is also used by tumour cells to evade the immune system 13, 14 . However, the molecular mechanism underlying immune evasion by normal and cancerous stem cells in adult tissues remains poorly understood.
MicroRNAs (miRNAs) are critical regulators of development and cancer 15, 16 . MiRNAs have been shown to be expressed in a celllineage-specific fashion in the mammary gland 17 , and are functionally involved in mammary gland development 5, [18] [19] [20] [21] . Likewise, miRNAs display distinct expression patterns in different subtypes of breast cancer and are known to promote or suppress tumorigenesis [22] [23] [24] and regulate breast CSCs 25 . Despite this progress, relatively little is known about how miRNAs regulate the interaction of stem cells with the immune microenvironment.
In this study, we identified a critical role of miR-199a in promoting MaSC and TIC properties by direct repression of LCOR, a nuclear receptor corepressor that sensitizes cells to interferoninduced differentiation and senescence. The miR-199a-LCOR axis represents a conserved molecular pathway in normal and cancer stem cells that mediates their evasion from autocrine and immune microenvironment suppressive signals.
RESULTS

Systematic screening reveals the MaSC-promoting activity of miR-199a
To identify candidate miRNA regulators of MaSCs, we performed miRNA profiling of the Lin − CD24 + CD29 high MaSC-enriched basal population (hereafter denoted as P4) and the Lin − CD24 + CD29 low luminal population (P5) of primary mammary epithelial cells (MECs) isolated by fluorescence-activated cell sorting (FACS) from the mouse mammary gland ( Supplementary Fig. 1a ). Twenty-three miRNAs were significantly upregulated in P4 versus P5 by more than twofold (Fig. 1a ). On the basis of the degree of differential expression of miRNAs and their predicted messenger RNA targets of interest, we selected 7 of the 23 upregulated miRNAs (miR-204, miR-211, miR-1a, miR-133a, miR-133b, miR-199a and miR-23a) for further functional analysis. We used lentiviral vectors to transduce primary MECs to test these candidates in mammosphere assays in vitro and cleared fat pad (CFP) reconstitution assays in vivo ( Fig. 1b and Supplementary  Fig. 1a ). Interestingly, only miR-199a overexpression (OE) led to a significant increase in both assays (Fig. 1b) . We confirmed by quantitative PCR (qPCR) higher expression of both mature forms (3p and 5p) of miR-199a in P4 versus P5 cells (Fig. 1c ). In situ hybridization (ISH) confirmed elevated expression of miR-199a in basal cells compared with luminal cells in the mammary gland ( Fig. 1d ).
We next examined the ability of miR-199a to induce MaSC activity in total MECs (P3), P4 or P5 cells (Fig. 1e,f and Supplementary  Fig. 1b,c) . Ectopic miR-199a-OE enhanced stem cell activity of P4 cells in CFP repopulation assays (Fig. 1e) while the opposite was observed with miR-199a knockdown (KD) ( Supplementary Fig. 1d ). Importantly, ectopic miR-199a expression in P5 cells also increased the repopulation frequency, indicating that miR-199a can induce a stem cell-like state in luminal cells (Fig. 1f ). Characterization of the repopulated mammary gland tissues showed an increase in the basal/MaSC marker Keratin14 ( Fig. 1g and Supplementary  Fig. 1e ,f). Serial passage and transplantation assays further confirmed that an increased and sustained capacity of sphere formation, basal phenotype, and regenerating ability was induced by miR-199a in three successive generations of passage (Fig. 1h ,i and Supplementary  Fig. 1g ). Finally, to investigate the relevance of miR-199a in MaSC populations, we used the Lgr5 knock-in EGFP reporter mouse 26 to isolate Lgr5 + and Lgr5 − cells. A significant increase of miR-199a expression was observed in Lgr5 + versus Lgr5 − P4 cells (Fig. 1j ), consistent with reported higher MaSC activity of the Lgr5 + P4 population 26 . Overall, these results suggest that miR-199a functionally promotes MaSC activity.
miR-199a induces stem-cell-like gene signatures and is upregulated in CSC populations
To explore the downstream signalling of miR-199a, we used the immortalized human MEC line HMLE to stably overexpress miR-199a and perform expression profiling. Gene set enrichment analysis (GSEA) revealed that the miR-199a overexpression resulted in enrichment of gene sets related to MaSC 27 , CSC 28 , undifferentiated tumour cell populations and the claudin-low (CL) breast cancer signature 7 (Fig. 2a ). Conversely, negative enrichments of luminal differentiated signatures, CSC downregulated genes, undifferentiated and CL downregulated gene sets were observed after miR-199a overexpression ( Fig. 2a ). To further investigate the connection of miR-199a with MaSCs and breast cancer, we next applied a Euclidean centroid-based CL predictor and stratified the TCGA data set including the CL subtype, which has been linked to MaSCs on the basis of transcriptomic studies 7 . Notably, we observed a large overlap between CL tumours and MaSCs at the miRNA level, with miR-199a being one of the most significantly upregulated common miRNAs among MaSCs and CL tumours ( Supplementary Fig. 2a and Supplementary Table 1 ).
MaSCs resemble cells that undergo epithelial-mesenchymal transition (EMT) on the basis of gene expression signatures and activated pathways 29 . Additionally, gene expression profiles of MaSC populations overlap with claudin-low breast cancers, which harbour EMT-like properties and are enriched for TICs 27, 30 . Interestingly, although miR-199a is downstream of EMT signalling, being upregulated by TGF-β and TWIST1 ( Supplementary Fig. 2b ) as previously reported 31 , it did not induce EMT in HMLE cells by itself (Fig. 2b,c and Supplementary Fig. 2c ). However, miR-199a strongly potentiated sphere formation ( Fig. 2d ) and increased the expression of several stem cell transcription factors and markers (Fig. 2b,e and Supplementary Fig. 2d ), indicating miR-199a as a prominent downstream effector of EMT signalling to induce stemness while having no direct role in influencing epithelial or mesenchymal phenotypes. This is consistent with recent findings suggesting that TWIST1 controls tumour maintenance and stemness independently of its function in regulating EMT 32 , and the existence of mesenchymal-like 10 and epithelial-like CSCs 33, 34 .
To explore whether miR-199a might also be important in TIC/CSC populations, we isolated different TIC populations in various breast cancer models. We used Twist1-induced TICs in HMLE-Neu cells 10 , CD24 + /Thy1 + cells in the MMTV-Wnt-1 mouse breast tumour 35 , and the CD24 − /CD44 + population 8 in HCI-002 patient-derived xenografts (PDX) 36 . In all of these TIC/CSC populations, miR-199a displayed elevated expression compared with the bulk population ( Fig. 2f-h ). These data are consistent with a previous study showing upregulation of miR-199a in human breast CSCs 5 . Overall, these observations suggest miR-199a to be an important regulator of MaSCs and breast CSCs.
LCOR is a direct miR-199a target that suppresses MaSC activity and is downregulated in MaSCs and CSCs
To identify potential targets of miR-199a responsible for the observed phenotype, we focused on genes downregulated in MaSCs (P4) that are: predicted to have direct miR-199a-binding sites ( Fig. 3a and Supplementary Table 2 ), and downregulated after miR-199a-OE in HMLE and NMuMG cells ( Fig. 3b ). On the basis of these criteria, we selected Tox3, Rbm47 and Lcor as candidate functional targets of miR-199a ( Fig. 3a) . In functional assays for MaSC activity, only Lcor-KD increased both sphere formation in vitro and mammary gland reconstitution in vivo (Fig. 3c ). In addition, we validated that Lcor is highly expressed in the luminal compartment ( Fig. 3d,e and Supplementary Fig. 3a ), and especially in mature luminal cells (P5-CD61 − ) compared with luminal progenitors (P5-CD61 + ) ( Supplementary Fig. 3b ). We next confirmed that transient or stable miR-199a-OE consistently represses LCOR in 10 different normal and 
Sphere ratio (miR-199a/Ctrl) 8 SOX2  POU5F1  NANOG  KLF4  NR5A2  LIN28B  FOXD3  PARD6A  TWIST1  SNAI2  SOX9  SOX10  P63   THY1  ALDH1A1  ALDH1A2  ALDH2  LIFR  PROCR  KRT14  DLL1  DLL3  ABCG1  ABCG4  ABCG5  SEMA6A   CDH2  VIM  FN1  FSP1  SDC1  ACTA2  ELF5  ELF3  CDH1  EPCAM  DSP  TJP1 miR-199a-5p ( Fig. 3h ). Due to the length of the 3 UTR, we cloned it as two separate fragments: UP and DOWN ( Fig. 3h ,i). We confirmed direct targeting of the three binding sites in DOWN 3 UTR that can be blocked by mutations; however, the two sites in UP 3 UTR did not show repression by miR-199a. Overall, these data implicate Lcor as a major candidate downstream effector of miR-199a. We next examined the functional role of Lcor in the mammary gland. Ectopic overexpression of Lcor in P4 cells ( Supplementary  Fig. 4a ) decreased MaSC activity as measured in sphere-forming ( Fig. 4a ) and reconstitution assays ( Fig. 4b ). Conversely, Lcor-KD in P5 cells increased MaSC activity and phenocopied miR-199a overexpression ( Fig. 4c and Supplementary Fig. 4b ). Moreover, Lcor rescue in miR-199a-OE P4 cells completely nullified the MaSCpromoting effect of miR-199a, and suppressed the induction of stem cell transcription factors by miR-199a in HMLE cells (Fig. 4a,d and Supplementary Fig. 4 ). Likewise, LCOR-KD in HMLE cells increased sphere formation ( Supplementary Fig. 4d,e ), and LCOR-OE reduced it ( Supplementary Fig. 4f ). GSEA showed enrichment of the MaSC signature and the CL predictor gene set in HMLE-LCOR-KD cells versus control ( Fig. 4e ), consistent with the miR-199a-OE transcriptional changes. Moreover, LCOR is strongly downregulated in the Lgr5 + MaSC population ( Fig. 4f ). Consistent with its inverse expression with miR-199a in normal mammary gland, we also observed that Lcor is downregulated in various TIC populations ( Fig. 4g,h) .
The miR-199a-LCOR axis promotes TIC activities in ER − breast cancer
We evaluated the clinical relevance of the miR-199a-LCOR axis using the Buffa data set 37 . Interestingly, miR-199a displayed a poor prognosis value and LCOR a good prognosis in the oestrogenreceptor-negative (ER − ) patients but not in ER + patients ( Fig. 5a,b ). We confirmed miR-199a and LCOR as independent prognostic markers in a triple-negative breast cancer (TNBC)-specific data set 38 ( Supplementary Fig. 5a ,b). Additionally, LCOR mRNA is downregulated in TNBC compared with non-TNBC tumours (Supplementary Fig. 5c ), and the analysis of 209 human breast tumour tissues showed high miR-199a and low LCOR levels in TNBC by ISH and immunohistochemistry (IHC), respectively ( Fig. 5c ), with inverse correlation to each other ( Supplementary Fig. 5d ). In the NKI295 data set, LCOR also shows good prognosis for distant metastasis-free survival ( Supplementary Fig. 5e ). Overall, these analyses indicate that the miR-199a-LCOR axis is clinically relevant in ER − breast cancer. To investigate the functional relevance of the miR-199a-LCOR axis in ER − breast cancer, we next used PDX 36 in vivo using NSG mice ( Supplementary Fig. 5f ). Intriguingly, ectopic miR-199a expression significantly increased tumoursphere formation of the TNBC PDXs (HCI-001; HCI-002; HCI-009; and HCI-010) but not in the ER + PR + HCI-003 and HCI-005 ( Fig. 5d ). Likewise, LCOR-OE reduced tumoursphere formation in the TNBC PDXs, and nullified the tumoursphere-promoting effect of miR-199a ( Fig. 5d ). Consistent with the tumoursphere assays, miR-199a expression strongly increased tumour initiation of ER − PDXs ( Fig. 5e-g and Supplementary Fig. 5g ,h), but not in the ER + HCI-003 ( Supplementary  Fig. 5g ). Conversely, LCOR-OE reduced tumour initiation in HCI-001, HCI-002 and HCI-010 ( Fig. 5e-g ). In addition, miR-199a-OE stimulated the development of systemic metastasis of the weakly metastatic 4TO7 mouse tumour cells. Conversely, LCOR overexpression strongly suppressed metastasis of MDA-MB-231 breast cancer cells ( Fig. 5h ,i). Collectively, these data demonstrate that the miR-199a-LCOR axis, besides its function in regulating normal MaSCs, is also a critical modulator of CSCs/TICs in ER − breast cancer, which are known to be enriched in TIC/CSCs.
miR-199a-LCOR modulates the IFN-α response of normal and cancerous stem cells
LCOR is a corepressor of agonist-bound nuclear receptors (NRs), but can also directly bind to DNA through its HTH domain 39 . We generated a double-point mutation of the NR box (LSKLL to LSKAA) to abolish NR binding 40 , and a HTH domain deletion mutant defective in direct DNA binding ( Fig. 6a ). Co-immunoprecipitation revealed near complete loss of interaction of LSKAA with the ER (Supplementary Fig. 6a ), and immunofluorescence analysis confirmed that the HTH mutant maintains nuclear localization ( Supplementary  Fig. 6b ). Strikingly, disruption of the NR interaction did not diminish the ability of LCOR to suppress sphere formation of HMLE cells while HTH lost such function (Fig. 6b ). These results suggest that LCOR acts through DNA binding to suppress stem cell properties.
Global transcriptomic profiling clustered LCOR-OE cells together with LCOR-LSKAA, and LCOR-HTH with control cells (Fig. 6c ). Using GSEA, we observed that the most enriched gene sets in LCOR-OE cells were related to the IFN-α and IFN-γ responses ( Supplementary Table 3 ). Importantly, the HTH mutant, but not LSKAA, completely lost this enrichment of the IFN-α signature ( Fig. 6d and Supplementary Table 3 ). Consistently, LCOR-KD HMLE and MDA-MB-231 cells showed a strong negative enrichment of the IFN-α response gene set ( Fig. 6e ). Such negative enrichment is also observed in HMLE-miR-199a-OE cells, suggesting that miR-199a, * * through LCOR repression, reprogrammes the transcriptome to suppress the IFN-α response. We further performed GSEA of the same gene sets in stem-cell-enriched populations versus non-stem cell populations. Strikingly, the IFN-α signature showed negative enrichment in P4-MaSC, and this negative enrichment bias was even more accentuated in the Lgr5 + MaSCs (Fig. 6f ). Similar negative enrichment of the IFN-α signature was also observed in ER − CD24 − /CD44 + breast CSCs 9 (Fig. 6g ). These findings further suggest a muted interferon response in MaSCs and breast CSCs.
To directly evaluate the functional importance of interferon signalling in stem cell regulation, we performed mammosphere assays using P4 and P5 (luminal cells have high sphere formation capacity due to progenitor proliferation 41 ) treated with IFN-α and IFN-γ. The P5 cells, which have higher LCOR levels, responded to the IFN-α treatment with reduced sphere formation ability ( Fig. 6h and Supplementary Fig. 6c ). In contrast, P4 cells showed an increase in sphere formation ( Fig. 6h and Supplementary Fig. 6c ), suggesting that MaSCs and luminal cells respond differently to IFN-α.
Interestingly, stem-cell-related genes (in red) were upregulated in P4 spheres and downregulated in P5 spheres following IFN-α treatment (Fig. 7a ). Moreover, luminal differentiation genes (in blue) were upregulated in P5, and not in P4, following IFN-α treatment ( Fig. 7a ). GSEA revealed enrichment of luminal and differentiated gene sets in P5 cells after IFN-α treatment, while MaSC and stemness gene sets were enriched in P4 treated cells ( Fig. 7b ). Consistent with the genomic profiling result, IFN-α induced the basal/MaSC marker K14 in P4 spheres, and the luminal marker K8 in Lcor-OE P4 spheres ( Supplementary Fig. 7a ). To further investigate the IFN-α effects in vivo, we performed CFP injections of P4 and P5, followed by IFN-α administration for 3 weeks. P4 cell reconstitution was slightly increased by the subcutaneous IFN-α treatment while P5 cell reconstitution was severely suppressed (Fig. 7c,d) , again highlighting the differential response of P4 and P5 cells to IFN-α in vivo.
We next determined how miR-199a and ectopic LCOR expression affects these responses to IFN-α. Ectopic expression of miR-199a in P5 prevented mammosphere reduction following IFN-α treatment ( Fig. 7e ), while Lcor expression in P4 and HMLE cells sensitized them to the suppressive effect of IFN-α ( Fig. 7f and Supplementary  Fig. 7b ). Similarly, IFN-α treatment in the HCI-010, a PDX highly enriched in TICs (Fig. 5e ), did not reduce sphere formation; however, LCOR-OE sensitized HCI-010 to IFN-α-induced reduction of tumourspheres ( Supplementary Fig. 7c,d) . In contrast, IFN-α treatment in miR-199a-OE or LCOR-KD HCI-010 cells increased (e,f) Quantification of mammospheres formed by 10,000 P5 (e) and P4 (f) cells with or without IFN-α treatment after transduction of the indicated constructs (n = 3 biologically independent samples; data represent mean ± s.e.m.). Plots represent the enhanced difference of treated conditions versus the control conditions (without treatment). (g) Tumour take rate following MFP injection of 10,000 control and miR-199a-OE HCI-001 cells, with or without treatment with 100,000 U IFN-α as indicated in the schematics. P value calculated by one-way ANOVA of the tumour incidence. (h,i) Quantification of PDX cell tumourspheres formed by 10,000 HCI-001 cells, with the indicated conditions (n = 3 biologically independent samples; data represent mean ± s.e.m.). (j) Senescence-associated β-galactosidase (SA-β gal) assay of MDA-MB-231 cells comparing control and LCOR-OE cells, and with or without IFN-α treatment for 72 h (n = 3 biologically independent samples; data represent mean ± s.e.m.; source of data in Supplementary Table 4 ). Scale bars, 2 mm (c,d) and 100 µm (j). * P < 0.05, * * P < 0.01, * * * P < 0.005 by two-tailed Student's t-test in a,e,f,h and i.
sphere formation ( Supplementary Fig. 7c,d ), suggesting that the TIC-enriched population resists the interferon blockage on sphere formation. Another PDX line (HCI-001), which has relatively lower TIC activity, is sensitive to IFN-α treatment in vivo and in vitro ( Fig. 7g-i) , but was rendered insensitive to IFN-α after miR-199a-OE ( Fig. 7m,n) or LCOR-KD (Fig. 7i ).
Overexpression of WT but not the HTH mutant of LCOR partially induced senescence in MDA-MB-231 and HMLE cells, and strongly sensitizes them to interferon-mediated senescence ( Fig. 7j and Supplementary Fig. 7e ). Consistent with these findings, GSEA revealed a significant enrichment of the senescence gene set in LCOR-OE but not in HTH-OE HMLE cells, and a negative enrichment in miR-199a-OE HMLE cells ( Supplementary Fig. 7f ). Overall, these findings indicate that the miR-199a-LCOR axis modulates the sensitivity of normal and cancerous stem cells to the differentiation and senescence effects of IFN-α.
MaSCs and breast CSCs are protected from suppressive effects of immune and autocrine IFN-α
To investigate the expression levels and sources of IFN-α in the mammary gland during different physiological and malignant states, we performed flow cytometry after co-staining intracellular IFN-α with various lineage markers of immune cells. Importantly, virgin mice already had a presence of IFN-α-expressing cells in the mammary gland and a substantial increase was observed during pregnancy, lactation and involution ( Fig. 8a and Supplementary Fig. 8a) . Interestingly, most of the IFN-α-expressing cells were macrophages across all of the different stages of the mammary gland, while T cells and dendritic cells were a relatively insignificant source of IFN-α ( Fig. 8b) . Importantly, high levels of infiltration ( Fig. 8c ) and activation (Fig. 8d ) of macrophages in the mammary gland were observed during lactation and involution. In addition, the macrophages from the virgin mammary glands already expressed more interferons than peritoneal macrophages ( Supplementary Fig. 8b ). Besides immune cells, a small source of IFN-α-expressing cells corresponded to the Lin − CD24 + epithelial cells (Fig. 8b) . This IFN-α-positive population increases significantly during pregnancy, consistent with the major expansion of the epithelial tissue at this stage. In breast tumours, different tumour types also showed elevated IFN-α levels and increased infiltration of IFN-α-positive macrophages (Fig. 8a,c,e and Supplementary Fig. 8a ).
We next isolated F4/80 + macrophages from the mammary gland at different states to generate conditioned media (CM) and validated IFN-α secretion by enzyme-linked immunosorbent assay (ELISA) (Fig. 8e) . Interestingly, CM of mammary gland macrophages significantly increased P4 and decreased P5 sphere formation, but such an effect was lost after miR-199a-OE in P5 cells (Fig. 8f,g) . The effect of CM from mammary gland macrophages on P5 spheres was abolished after treatment with neutralizing antibodies against IFN-α/β (Fig. 8g ), proving that these effects were mediated by IFNs. Moreover, neutralizing antibodies against IFN-α/β consistently increased P5 and P4-Lcor-OE sphere formation even without the presence of immune cells (Fig. 8h ), indicating that P5 or P4-Lcor cells are also constrained by autocrine IFN-α/β signalling. Similarly, mammary gland macrophage CM also reduced the HCI-001 tumoursphere formation, and this was avoided by miR-199a-OE (Fig. 8i ). These results demonstrate that, by virtue of elevated miR-199a expression and reduced LCOR levels, both normal and cancerous stem cells are protected from immune or autocrine/paracrine interferon-mediated suppressive effects.
To further explore the clinical significance of the miR-199a-LCOR-IFN-related regulatory pathway in breast cancer, we generated an IFN-Stem Cell-Down signature (ISDS) from the Interferon-αresponse gene set (M5911) to represent interferon-α-responsive genes that are regulated by the miR-199a-LCOR axis and also contribute to negative enrichment of the M5911 in normal and cancerous stem cells. The combined 27 genes constitute the ISDS (Fig. 8j) and have a good prognosis value for relapse-free survival, overall survival and distant metastasis-free survival in ER − breast cancer patients from the KM plotter data set 42 (Fig. 8k-m) . The individual analysis of the ISDS genes in ER − breast cancer showed a good prognosis value for all of them, with 21 out of 27 being significant ( Supplementary Fig. 8c ), highlighting the clinical relevance of the miR-199a-LCOR-IFN axis in ER − breast cancer.
DISCUSSION
In this study, we identified a miRNA-199a-mediated pathway shared by both MaSCs and breast CSCs to maintain their self-renewal competence and avoid differentiation or senescence induced by suppressive immune cytokines such as IFN-α ( Fig. 8n ). MiR-199a has been reported to have either tumour-suppressive functions 43, 44 or tumour-promoting activities 45 across different cancer types, including breast cancer 46, 47 . Here, we provide evidence for an important functional role of miR-199a in promoting MaSC activity by directly repressing LCOR, a nuclear receptor corepressor. LCOR has been proposed as a tumour suppressor in prostate cancer 48 ; however, there is no previous report of LCOR function in mammary gland development or breast cancer. We identified LCOR as a direct functional target of miR-199a in regulating MaSC and breast CSC activities. Our experimental and clinical data show that the miR-199a-LCOR axis mainly influences tumorigenesis of ER − breast cancer, suggesting that LCOR is not acting through ER binding. This is also consistent with our results showing the maintenance of LCOR function in the LSKAA mutant. Therefore, the LCOR action on stem cells and breast cancer is independent of the ER, which is consistent with its function in MaSCs (which are ER − ) and ER − breast cancer.
Exploring the downstream effects of miR-199a-LCOR, we showed that LCOR negatively regulates stem cells by sensitizing them to interferon responses. Interferon signalling is known to be critical in anticancer immune surveillance of primary tumours and metastases 49, 50 . Interferons can also induce tumour cell-intrinsic inhibitory effects, including differentiation, growth arrest, and cell death 50, 51 . However, less is known about the effects of interferon on stem cells. Some studies have found different effects of IFN-α on haematopoietic stem cells, as it can activate dormant haematopoietic stem cells (HSCs) but inhibit active HSCs 52 , or drive exhaustion of quiescent HSCs 53 . Therefore, IFNs can play opposite roles in stem cell fate in the haematopoietic system, depending on target cell status and on acute or chronic signalling 52 . Whether this is also the case in other adult stem cell systems and in cancer stem cells was unknown. Here we show that IFN can have different effects on MaSCs or differentiated cells, depending on the status of the miR-199a-LCOR axis. Remarkably, we found that IFN-α response is attenuated in normal and malignant stem cell populations on the basis of GSEA, indicating that low IFN sensitivity is a critical and general mechanism to maintain the stem cell phenotype.
Taken together, our study reveals a miR-199a-LCOR-IFNdependent mechanism that is commonly used by MaSCs and CSCs to escape from differentiation and senescence induced by IFN signalling, which is particularly relevant during mammary gland lactation and involution 54 , and in immune cell-rich claudin-low and TNBC tumours 7, 55 . Moreover, normal stem cells may use this mechanism to acquire immune privilege properties, as they do by downregulating MHCs to ensure tissue homeostasis. Since MHCs are regulated by IFN 12 , stem cells may downregulate MHCs by suppressing IFN signalling. Accordingly, CSCs are less responsive to IFN and can escape immune surveillance, which is a critical ability during tumour and metastasis initiation events 56, 57 . However, CSCs may have a defective antiviral interferon-mediated response, which may explain why oncolytic viruses specifically target CSC populations 58, 59 . In fact, the interferon response is frequently defective in multiple cancer types IFI27  MX1  RTP4  SAMD9L  IFITM1  BST2  B2M  IFI44  USP18  ISG15  OASL  DHX58  TXNIP   PLSCR1  IRF9  IFIT2  STAT2  UBE2L6  NMI  CD74  IFIT3  PARP9  IL4R  IFIH1  SP110  ISG20 by genetic or epigenetic alteration of related genes 60, 61 , suggesting that defective IFN responses are advantageous for tumours. As IFNs have been widely used as adjuvant therapy in multiple cancer types, such treatments may become more effective if the IFN-resistant CSCs can be rendered sensitive by targeting the miR-199a-LCOR axis.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb3533 METHODS Animal studies. Animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Princeton University. For mammary stem cell isolation, 8-to 9-week-old female FVB virgin mice were used. The Lgr5-EGFP-IRES-creERT2 (C57/B6 background) model was used for MaSCs Lgr5 + isolation (Lin − CD24 + CD29 high GFP + ) as previously described 26 . For cleared fat pad injections, 3-to 4-week-old female FVB mice were anaesthetized and minimal incisions were made to expose the mammary gland. Randomization among litters was performed before the injection time, and animals were similar age and female sex (applies to the rest of the experiments using mice). No statistical method was used to predetermine the sample size (applies to the rest of the experiments using mice). Following the standard protocol, the mammary gland clearing was done above the central lymph node in inguinal gland no. 4, and different quantities of cells (as indicated in the figures or figure legends) were injected into the cleared fat pad as previously described 62 . The investigators were not blinded to allocation during experiments and outcome assessment. For the IFN-α treatment experiment, 100,000 U of recombinant mouse IFN-α2 was subcutaneously administered 48 h after surgery, three times a week for three weeks. A MMTV-Wnt1 mouse model of spontaneous breast cancer was used to isolate mouse tumourinitiating cells. MMTV-PyMT and MMTV-Wnt1 mouse models of spontaneous breast cancer were used to measure the IFN-α levels in various immune cell populations in tumours and to isolate macrophages. For orthotopic mammary tumour experiments of human patient-derived xenografts (PDX; kindly provided by A. Welm, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA) including HCI-001, HCI-002, HCI-003, HCI-005, HCI-009 and HCI-010, immunocompromised NOD Scid Gamma (NSG) mice were used. Note that NSG mice lack mature T cells, B cells and NK cells, but they have dendritic cells and macrophages, although with reduced activity 63, 64 . We followed the standard protocol for PDX transplantation, maintenance and digestion of the tumours 36 . The lentiviral transduction and orthotopic injections of PDX single-cell suspension were optimized for primary tumour initiation experiments. Six to ten mice or glands were used for each experimental group and the primary tumours were monitored weekly by palpation. For the IFN-α treatment experiment, subcutaneous injection of 100,000 U of recombinant human IFN-α2A was administered three times a week for 50 days, starting at day 30 after tumour inoculation (prior to the formation of palpable tumours) and ended at the endpoint of the experiment (Fig. 6m) . Tumour monitoring and measurement were performed by trained technicians in a blinded fashion. Tumours were measured by callipers for calculation of tumour volumes (π × length × width 2 /6). For systemic metastasis experiments using 4TO7 and the MDA-MB-231 cell line, intracardiac injection of 100,000 cells in the left ventricle was performed in anaesthetized female athymic Ncr-nu/nu mice. Development of metastases was monitored by blinded investigators and measuring the photon flux of metastatic lesions based on bioluminescence imaging as previously described 65 , and nodule counts were obtained after dissection of the different organs (investigators were not blinded to outcome assessment).
Cell lines, culture conditions and treatments. All cell lines used in the study, including mammary epithelial cell lines (human HMLE, MCF10A and mouse NMuMG cell lines), breast cancer cell lines (human MDA-MB-231, HMLE-Neu, T47D, MCF7, BT474, and mouse 4TO7 cell lines) and other cell lines (HEK293T, H29 and HeLa), were cultured using the standard conditions according to the American Type Culture Collection (ATCC) instructions. HMLE and HMLE-Neu cells were obtained from R. Weinberg at MIT, USA. iMMEC cells were obtained from V. Karantza at CINJ, USA. Primary isolated mammary epithelial cells (MECs) were cultured with MEGM (Lonza) and immortalized murine MECs (iMMECs) were cultured as described previously 66 . No cell lines used in this study were found in the database of commonly misidentified cell lines that is maintained by ICLAC and NCBI Biosample. The cell lines were not authenticated. Mycoplasma contamination was routinely checked for (monthly) in the laboratory by PCR analysis; all cell lines used in the study were confirmed to be mycoplasma negative. TGF-β1 (R&D systems) and Z-4-hydroxytamoxifen (4-OHT) (Sigma-Aldrich) cell culture treatments in vitro were performed for 12 days, at 100 pM and 20 nM, respectively.
Limiting dilution assays. For mammary gland reconstitution assays, we prepared single-cell suspensions of MECs and sorted for P4/P5 cells by flow cytometry. Lentivirally transduced cells were injected in serial dilution numbers into cleared mammary fat pads. Cells were injected in 50% Matrigel and outgrowth was analysed after 6 weeks. ELDA (extreme limiting dilution analysis) software was used to calculate the frequency of MaSCs with 95% of confidence. The same quantitative method was used in limiting dilution mammary fat pad injections of PDX cells to calculate TIC frequency. The PDX transduced singlecell suspensions were also injected in 50% Matrigel into the mammary fat pad of NSG mice. Tumours were considered established when they became palpable for 2 consecutive weeks.
Viral production and infection of cell lines and primary cells. Lentiviral plasmids
were transfected into HEK293T cells together with the envelope plasmid (VSVG) and gag-pol plasmid (pCMV-dR8.91) following the standard lentiviral packaging protocol to generate lentiviruses. For retrovirus, the pWZL-ER-Blast retroviral vectors were transfected into the H29 packaging cell line and viruses were collected 48 and 72 h after transfection. Primary cells were spin infected in conical tubes for 2 h at 1,000g at 4 • C with concentrated viruses in media containing 8 µg ml −1 Polybrene. After spin infection, cells were counted and used for in vitro or in vivo experiments. For established cell lines, cells were transduced in culture and selected with the corresponding antibiotic resistance.
Immune cell isolation. F4/80 + macrophages were obtained by FACS from 3 day involuting mammary glands of 9-10-week FVB mice. Primary cells were cultured in mammosphere media (MSM) for 48 h to generate the CM, which was then used to treat mammospheres.
Senescence assays. Cell lines were cultured and senescence was evaluated after 2-3 days of IFN-α treatment (1,000 U ml −1 human IFN-α2A) using the β-Galactosidase staining kit (Cell Signaling Technology) following the manufacturer's instructions. Images were taken with a 10× objective in bright field.
Molecular cloning and plasmids. Multiple miRNA (mouse miR199a-2, miR-204, miR-211, miR-1a, miR-133a, miR-133b, miR-23b) and gene (mouse Lcor and human LCOR-HA, LCOR-LSKAA-HA and LCOR-∆HTH-HA) expression constructs were generated using the pLEX-MCS-Puro lentiviral vector. cDNA was introduced into pLEX using the SpeI and AgeI cutting sites. For LCOR-HA, LCOR cDNA was first introduced into pRVPTO-HA using EcoRI and NotI. The resultant LCOR-HA was then subcloned into the pLEX-MCS using SpeI and AgeI. The LCOR mutants (LCOR-LSKAA-HA and LCOR-HTH-HA) were generated from the pLEX-LCOR-HA construct by two separate PCR amplifications with the mutation region joining the two PCR fragments. The 5 fragment was amplified using a forward primer paired with specifically designed mutation-containing reverse primers, which end on the intended mutation region or right before it. The 3 fragment was amplified using the mutation-containing forward primers paired with a reverse primer. To enable blunt end ligation and cloning, the mutantharbouring primers were phosphorylated using T4 kinase before the PCR reactions. The amplified 5 and 3 fragments were digested with SpeI and AgeI respectively and ligated into the pLEX-MCS. Retroviral tamoxifen-inducible overexpression plasmids pWZL-ER-Blast and pWZL-Twist1-ER-Blast were obtained from Addgene. For miR-199a knockdown, miRZIP technology from System Biosciences was used to generate pGreenPuro (scrambled hairpin control), miR-ZIP-199a-5p and miR-ZIP-199a-3p. For gene knockdown studies, shRNA lentiviral vectors were purchased from Sigma-Aldrich for targeting mouse genes Lcor (TRCN0000085107), Tox3 (TRCN0000413123) and Rbm47 (TRCN0000123514), and human LCOR (TRCN0000016306 and TRCN0000436034). The pMIR-REPORT vector (Ambion) was used to generate luciferase reporters for miRNA targeting activity. Wild-type and mutant mouse Lcor 3 UTRs were cloned into pMIR-REPORT using SpeI and HindIII sites. The 3 UTR-Lcor sequence was divided into UP and DOWN segments, as the full-length 3 UTR exceeded 8 kb and could not be cloned in its entirety. Single and double mutants were generated for the five different predicted seed sequences. Mutated 3 UTR seed sequences were generated using the QuikChange multi site-directed mutagenesis kit (Stratagene). All primer sequences used for cloning are listed in Supplementary Table 5 (restriction sites are in green and mutated nucleotides are in red and bold).
Flow cytometry analysis and cell sorting. For mammary gland lineage cell isolation, we followed the standard protocol used previously 62 . Briefly, mammary glands from 8-9-week-old female mice were digested to form single-cell suspensions of primary MECs. These cells were sorted using Lin − CD24 + CD29 high markers to obtain P4 (MaSCs/basal) cells, Lin − CD24 + CD29 low markers to obtain P5 (luminal) cells, and total Lin − for P3 (total MECs). We used CD61 + to isolate luminal progenitors and CD61 − for mature luminal cells within the P5 population. For Lgr5 + MaSC isolation, the Lgr5-EGFP-IRES-creERT2 mice were used and Lgr5 + MaSCs were isolated by FACS using the Lin − CD24 + CD29 high GFP + marker combination. F4/80 + primary macrophages were isolated by FACS from single-cell suspensions of digested mammary glands from FVB mice. Mouse TICs were obtained from MMTV-Wnt1 tumours after sorting for the CD45 − CD24 + Thy1 + population. Digestion of PDX tumours and preparation of single-cell suspensions were performed using the standard protocol 36 and human primary TICs were isolated by sorting the Lin − CD24 − CD44 + population.
Intracellular IFN-α flow cytometry analysis. Mammary glands and tumours were digested and brought to single-cell suspension as described above and with the presence of GolgiPlug as indicated by the manufacturer (BD Biosciences). After fixation with 2% paraformaldehyde 30 min on ice, cells were permeabilized and blocked with 0.2% saponin, 5 mM EDTA, 2 mM NaN 3 , 5% NGS and 4 µg ml −1 anti-Fcγ receptor (Clone 2.4 G2; BD Biosciences). IFN-α was stained using FITCconjugated anti-mouse IFN-α (Clone RMMA-1; PBL) 67 . T cells were stained with PE anti-mouse CD3ε (Clone 145-2C11; BioLegend), macrophages with APC/Cy7 antimouse F4/80 (Clone BM8; BioLegend), and dendritic cells with APC anti-mouse CD11c (Clone HL3; BD Pharmingen). FITC-conjugated rat IgG1 was used as a negative isotype control (Clone RTK2071; BioLegend). Note, pregnancy, lactation and involution cell samples display small levels of autofluorescence for reasons unknown. We thoroughly excluded this population from our analysis and applied the same gating for all the samples.
Histological analysis, immunohistochemistry (IHC), immunofluorescence (IF) and in situ hybridization (ISH). Histology, IHC and IF analysis of mouse mammary and tumour tissue samples was done as previously described 68 using the antibody and dilution ratios listed in Supplementary Table 6 .
For IHC analysis of clinical specimens, paraffin slides of 4 µm thickness or tissue microarrays were baked overnight at 60 • C. Tissue slides were washed with PBS after deparaffinization and hydration and then boiled in citrate buffer at 100 • C for 40 min. After treatment with 3% H 2 O 2 for 30 min to block endogenous peroxidase, slides were incubated at 4 • C overnight with rabbit anti-human LCOR antibody (Sigma). Following washes with PBS, slides were then incubated with HRP-conjugated goat anti-rabbit secondary antibody (Genetech) for 30 min at room temperature. Sections were stained by DAB and then counterstained with Gill haematoxylin.
IF analysis of cell culture was performed in HMLE cells using anti-HA to determine the localization of ectopically expressed LCOR-HA. Sterile coverslips placed at the bottom of 24-well plates were seeded, washed with PBS, and fixed for 1 h with methanol at −20 • C. After fixation, samples were washed with acetone, then 5 times with PBS, blocked for 30 min with blocking buffer (5% normal goat serum, 0.5% Triton X-100 in PBS) and incubated with anti-HA for 2 h at room temperature. This was followed by PBS washes, and 1 h incubation with secondary antibody conjugated with Alexa Fluor 488. Images were taken using a Nikon A1 confocal microscope and Zeiss fluorescence microscope. For mammosphere staining, spheres were collected with a 5 min spin at 450g , fixed with PFA 4% for 15 min at 4 • C and washed with PBS, followed by centrifuge colony precipitation. Blocking was performed using PBS-Tween 0.3% and M.O.M. kit blocking reagent (Vector Laboratories), followed by 1 h co-staining with anti-Keratin-14 and anti-Keratin-8, and then by 1 h incubation with the respective species-specific secondary antibodies.
For mammary gland ISH experiments, we used the miRCURY LNA microRNA ISH Optimization Kit from Exiqon. LNA probes were double DIG labelled to specifically detect miR-199-5p and U6 snRNA as a positive control (Exiqon). The manufacturer's protocol was strictly followed to perform the ISH in mouse and human samples. For clinical breast cancer ISH, paraffin slides (4-µm thick) of paraformaldehyde-fixed tissues were baked overnight at 60 • C, deparaffinized and hydrated, and then washed with phosphate-buffered saline (PBS). To block endogenous peroxidase activity, slides were treated with 3% H 2 O 2 for 10 min at room temperature. After pepsin digestion for 30 min at 37 • C, slides were incubated with pre-hybridization buffer (all reagents from sensitivity enhanced in situ hybridization kits, Boster) for 3 h at 37 • C. Slides were hybridized with double digoxigeninlabelled probes (30 nM for miR-199a, 30 nM for the internal control U6, Exiqon) in hybridization buffer at 65 • C overnight, and then washed sequentially with 2× SSC, 1× SSC and 0.2× SSC buffers. Slides were incubated sequentially with the following reagents: blocking buffer, biotinylated digoxin, streptavidin-biotin complex, and peroxidase. Sections were stained by 3,3-diaminobenzidine (DAB) and then counterstained with Gill haematoxylin.
Mammosphere and tumoursphere assays. For mammosphere and tumoursphere assays, single cells were plated in ultralow-attachment plates (Corning) with the standard mammosphere media 69 . The number of cells plated is indicated for each specific experiment in the figures. The mammospheres were counted 5-12 days later depending on the experiment, which is indicated in figure legends. Tumourspheres were counted after 5-8 days. For multiple-generation sphere formation experiments, colonies were collected by 2 min centrifugation at 200g and dissociated with trypsin for 5 min at 37 • C. Single dissociated cells were then centrifuged and counted to allow seeding of equal numbers of cells for the next round of sphere formation assays.
Interferon treatment (1,000 U ml −1 ) was started 24 h after cell seeding. Recombinant mouse IFN-α2 and IFN-γ were purchased from Novoprotein. Neutralizing antibodies against mouse IFN-α (clone RMMA-1, PBL) and IFN-β (clone RMMB-1, PBL) were used at 2.5 µg ml −1 . Conditioned medium (CM) was generated by culturing primary immune cells in mammosphere medium (MSM) for 48 h, using 1 ml of MSM for every 600,000 primary cells seeded.
Tissue microarrays and other tumour samples. A total of 200 stage I to III primary breast cancer samples from females with invasive ductal carcinoma were randomly collected at the Fudan University Shanghai Cancer Center (FUSCC) between March 2003 and January 2008. Tissue microarrays were constructed using paraffin-embedded blocks of these samples, consisting of duplicate cores from different areas of the same tumour to compare staining patterns. We also included nine cases of primary metaplastic carcinoma diagnosed in the same time period. Paraffin-embedded sections were used for in situ hybridization and immunohistochemical staining. We used the staining index to interpret the staining of miR-199a and LCOR. Briefly, the staining score was determined by three independent researchers blinded to the tumour information. Each sample was scored as weak (1) or strong (2) according to staining intensities and the average of the resultant scores was computed. Our study was approved by the independent ethics committee/institutional review board of FUSCC (Shanghai Cancer Center Ethics Committee). All patients gave their written informed consent before inclusion.
Murine IFN-α ELISA. Specific cell populations (500,000 cells) were plated for 48 h with subsequent collection of conditioned media for cytokine quantification. IFN-α levels were quantified from the CM for all cell cultures using the mouse IFN-α Platinum ELISA kit (Fisher/eBioscience) following the manufacturer's instructions.
Luciferase reporter assays. Wild-type and mutant pMIR-LCOR-3 UTR reporters were transfected into HeLa cells together with the Renilla-luciferase control plasmid (Ambion). Reporter plasmid (200 ng) was co-transfected with the Renillaluciferase control plasmid and 10 pM of miRNA mimics (Applied Biosystems; Life Technologies). Lipofectamine 2000 was used as the transfection reagent. Cells were lysed 24 h after transfection and analysed for luciferase activity using the Glomax 96 Luminometer (Promega).
qRT-PCR analyses. Total mRNA and miRNAs were isolated using the mirVana miRNA isolation Kit (Ambion). mRNA reverse transcription was done using Superscript III kit (Invitrogen) and real-time quantitative PCR performed using the Power SYBR green PCR master mix (Applied Biosystems). miRNAs were reverse transcribed using the TaqMan Reverse Transcription Kit (Applied Biosystems) and followed by real-time qPCR using TaqMan miRNA assays (Applied Biosystems). All analyses were performed using an ABI 7900HT PCR machine. mRNA expression was normalized by the expression of GAPDH, and miRNA expression by RNU6B in each sample. qRT-PCR primers used are listed in Supplementary Table 5 .
Immunoprecipitation and western blot analysis. For immunoprecipitation (IP) experiments, cells were lysed in IP lysis buffer (20 mM Tris pH 7.4, 0.15 M NaCl, 1 mM EDTA, 1 mM EGTA, 1% Tx-100) with complete protease inhibitor cocktail (Roche). Cell lysates were incubated on ice for 20 min, centrifuged, and incubated with 5 µg of anti-HA (Abcam, Ab9110) at 4 • C overnight. Protein G magnetic beads (Life Technologies) were pre-cleared and 20 µl were added to the sample for 2 h at 4 • C. Beads were washed 5 times and boiled with SDS Laemmli buffer to elute bound protein for western blotting (WB). For WB analysis of cultured cells, proteins were extracted using RIPA buffer and SDS Laemmli buffer. Gel preparation and immunoblotting were performed according to standard protocols. Antibodies and dilutions for WB are listed in Supplementary Table 6 .
Microarray analysis. The P4 and P5 subpopulations of mammary epithelial cells (MECs) were isolated from the mammary glands (4-5 mammary glands from each group) of 8-9-week-old virgin FVB or Lgr5-EGFP-IRES-creERT2 mice. MECs were isolated using FACS as previously described 62 . Total RNA was prepared from MECs and various human cell lines including HMLE-miR-199a, -LCOR variants and -LCOR-KDs or MDA-MB-231 LCOR-KD cells, using the mirVana kit as described above. P4 and P5 with IFN-α treatment (1,000 U ml −1 ) were maintained in mammosphere conditions during 8 days of mammosphere culture. The expression of miRNA in MEC subpopulations was determined using Agilent mouse miRNA_V19 array (G4872A). The RNA samples were labelled and hybridized using a miRNA complete labelling and hybridization kit (Agilent, 5190-0456). The expression of mRNA in MECs was determined with Agilent Mouse GEv1 8x60K Microarray (G4852A). The mRNA expression in human cell lines was determined with Agilent human GEv2 8x60k microarray (G4851B). The mRNA microarray analyses were performed using a two-colour system. Briefly, the RNA samples and universal mouse reference RNA (Agilent 740100) were labelled with CTP-cy5 and CTP-cy3, respectively, using the Agilent Quick Amp Labeling Kit. Labelled testing and reference RNA samples were mixed in equal proportions, and hybridized to the arrays as described above. After hybridization, the miRNA and mRNA arrays were scanned with an Agilent G2565BA scanner and raw data were extracted using Agilent Feature Extraction software (v10.7). Data were analysed using the GeneSpring GX software (Agilent). In brief, for one-colour miRNA array data, the intensity values of multiple probes for the same miRNA are first summed up and In the format provided by the authors and unedited.
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